mercredi 4 mai 2016

Onco Actu du 4 mai 2016

1.1 Biologie - Gènes

DNA analysis brings scientists step closer to ‘complete picture’ of breast cancer [Cancer Research UK]

2.6 Etiologie - Environnement

Polluted air may up risk of many cancers [Reuters]

3.1 Tabac

EU's highest court upholds restrictive new law on cigarettes [Reuters

4.5 Dép., diag. & prono. - Colorectal

Colonoscopies get the glory, but reasons for dramatic decline in colon cancer are unclear [HealthNewsReview]

5.12 Immunothérapies

Global Cancer Immunotherapies Market 2016-2020 [ReportsnReports]

5.2 Pharma

FDA Grants Priority Review for Lilly's Olaratumab, an Investigational Medicine for Advanced Soft Tissue Sarcoma [Lilly]

5.2.2 Pharma - Fusions & Acquisitions

Pfizer considers a move on Medivation [PharmaTimes]

5.2.3 Pharma - économie

Celgene, Novartis back $46M Series A in next oncology play from Flexus execs [FierceBiotech]

Biotech’s behind-the-scenes baroness redefined how universities launch startups [STAT]

The World’s Most Expensive Medicine Is a Bust [MIT Techonology Review]

Pfizer Guides Higher, Mulls Breakup of Company [Wall Street Journal]

5.3 Traitements - FDA, EMA,...

Genomic Data and Drug Development: EMA Offers New Draft Guidance [RAPS]

What We Mean When We Talk About EvGen Part II: Building Out a National System for Evidence Generation [FDA Voice]

6. Lutte contre les cancers

Set up a public registry of competing interests [Nature News & Comment]

6.7 DMP, Big Data & applis

Quintiles, IMS Health unveil surprise megamerger [FierceBiotech]

Quintiles and IMS Health announce plans to merge [PharmaTimes]

Google given access to London patient records for research [BBC News]

6.9 Controverses

The gene editor CRISPR won’t fully fix sick people anytime soon. Here’s why [Science]

Johnson & Johnson hit with $55m damages in talc cancer case [BBC News]

Why can’t all illnesses get the cancer treatment? [The Guardian]